TLC - Taiwan Liposome inks deal with Zydus to launch AmphoTLC in India

Taiwan Liposome (TLC) and Zydus Healthcare have signed a license supply and commercialization agreement for AmphoTLC (Amphotericin B Liposome for Injection 50mg) in India.AmphoTLC is indicated for severe systemic fungal infections such as mucormycosis. Under the terms of the agreement, TLC will manufacture and supply AmphoTLC on a non-exclusive basis to Zydus, and Zydus will commercialize AmphoTLC in India.TLC shares down 7% premarket trading at $5.91. TLC has obtained the necessary approvals for AmphoTLC from the regulatory authorities in India with the assistance of Zydus, including a new drug registration on May 25, 2021, for immediate importation as per approved usage and indication of liposomal amphotericin B.

For further details see:

Taiwan Liposome inks deal with Zydus to launch AmphoTLC in India